Buscar
Mostrando ítems 1-10 de 12
Senescent synovial fibroblasts accumulate prematurely in rheumatoid arthritis tissues and display an enhanced inflammatory phenotype
(BMC, 2019-11-05)
[Abstract] Background
Accumulation of senescent cells has been associated with pro-inflammatory effects with deleterious consequences in different human diseases. The purpose of this study was to analyze cell senescence ...
Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis
(PLoS, 2018-05-07)
[Abstract] Genetic biomarkers are sought to personalize treatment of patients with rheumatoid arthritis (RA), given their variable response to TNF inhibitors (TNFi). However, no genetic biomaker is yet sufficiently validated. ...
Clinical, Patient-Reported, and Ultrasound Outcomes from an Open-Label, 12-week Observational Study of Certolizumab Pegol in Spanish Patients with Rheumatoid Arthritis with or without Prior Anti-TNF Exposure
(Elsevier, 2018-09-17)
[Abstract] Objectives: To assess the effectiveness and safety of certolizumab pegol (CZP) in Spanish patients with RA.
Materials and methods: SONAR (NCT01526434), a 12-week, open-label, prospective, observational, ...
A functional variant of TLR10 modifies the activity of NFkB and may help predict a worse prognosis in patients with rheumatoid arthritis
(Springer, 2016-10-04)
[Abstract] Background. Toll-like receptor (TLR) family members are key players in inflammation. TLR10 has been poorly studied in chronic inflammatory disorders, and its clinical relevance in rheumatoid arthritis (RA) is ...
A combined transcriptomic and genomic analysis identifies a gene signature associated with the response to anti-TNF therapy in rheumatoid arthritis
(Frontiers, 2019-07-02)
[Abstract] Background: Rheumatoid arthritis (RA) is the most frequent autoimmune disease involving the joints. Although anti-TNF therapies have proven effective in the management of RA, approximately one third of patients ...
Evaluación económica de la monoterapia con tocilizumab frente a adalimumab en artritis reumatoide
(Ministerio de Sanidad, Consumo y Bienestar Social, 2013)
[Resumen] Fundamento: Tocilizumab (TCZ) fue superior a adalimumab (ADA) en monoterapia en la reducción de los signos y síntomas de la artritis reumatoide del adulto (AR) en pacientes intolerantes o con respuesta inadecuada ...
Meta-analysis of Immunochip data of four autoimmune diseases reveals novel single-disease and cross-phenotype associations
(BMC, 2018-12-20)
[Abstract] Background. In recent years, research has consistently proven the occurrence of genetic overlap across autoimmune diseases, which supports the existence of common pathogenic mechanisms in autoimmunity. The ...
Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis
(Oxford University Press, 2014-12-19)
[Abstract] Objective. The aim of this study was to establish guidelines for the optimization of biologic therapies for health professionals involved in the management of patients with RA, AS and PsA.
Methods. Recommendations ...
Perceptions of patients with rheumatic diseases treated with subcutaneous biologicals on their level of information: RHEU-LIFE survey
(Elsevier, 2018-12-21)
[Abstract] Objective: To investigate, in Spanish patients with rheumatic diseases treated with subcutaneous biological drugs, their sources of information, which sources they consider most relevant, and their satisfaction ...
Adherence to synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results of the OBSERVAR study
(Elsevier, 2019-01-10)
[Abstract] Background: Treatment compliance with disease-modifying antirheumatic drugs (DMARD) is essential to achieve the therapeutic goals in rheumatoid arthritis (RA). However, despite the need for good compliance, there ...